Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

This study has been completed.
Sponsor:
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00224783
First received: September 20, 2005
Last updated: January 25, 2012
Last verified: January 2012
  Purpose

The primary objective of the study was to investigate the safety and tolerability of CAIV-T liquid formulation in healthy Japanese male adults.


Condition Intervention Phase
Healthy Japanese Male Adults
Biological: CAIV-T
Biological: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Placebo-controlled Double-blind Controlled Trial of Single Intranasal Inoculation of CAIV-T Liquid Formulation in Healthy Japanese Male Adults

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • The number of subjects within each treatment arm who experienced influenza-like symptoms [ Time Frame: Within 6 days post vaccination ] [ Designated as safety issue: Yes ]
    Influenza-like symptoms, ie, typical clinical symptoms of influenza infection, including fever (oral temperature > or = 38 degrees C), cough, runny or stuffy nose, sore throat, headache, chills, muscular pain, vomiting, decline in activity, decline in appetite.


Secondary Outcome Measures:
  • The number of subjects within each treatment arm who experienced adverse events [ Time Frame: Within 28 days of vaccination ] [ Designated as safety issue: Yes ]
    Adverse events were classified according to the "Glossary of Side Effects of Pharmaceutical Agents, 1996."


Enrollment: 45
Study Start Date: August 2002
Study Completion Date: September 2002
Arms Assigned Interventions
Active Comparator: CAIV-T
CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
Biological: CAIV-T
Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
Other Name: 0.2 mL, by nebulizer
Placebo Comparator: Placebo
Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
Biological: Placebo
0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).

Detailed Description:

The primary objective of the study was to investigate the safety and tolerability of CAIV-T liquid formulation in healthy Japanese male adults by evaluating the incidence of influenza-like symptoms, and the type, incidence, and severity of adverse events.

  Eligibility

Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age of 20 years old or over but below 45 years old (at the time of consent)
  • Persons judged suitable by the principal investigator or investigator from the results of prior history, physical examination and clinical findings.
  • Persons having the ability to understand consent and a written consent obtained prior to the start of screening.
  • Persons being able to participate in the trial for 1 month from the inoculation of the trial vaccine to the completion of the trial.
  • Persons being able to be contacted (by phone, hospital visit or house visit) by the trial staff at the time of testing after 28 days from the inoculation of the trial vaccine.

Exclusion Criteria:

  • Persons judged to be impossible or difficult to contact for requesting hospital visits to carry out clinical evaluation and tests during the trial term.
  • Persons having a prior history of or suspected immunological disease, or those receiving administration of systemic corticosteroids or immunosuppressants such as cytotoxic drugs (e.g., methotrexate, etc.)
  • Persons having blood formulations such as immunoglobulin, etc., administered or planned during a period from one month before the inoculation of the trial vaccine to the completion of the trial.
  • Persons living with any person with a nonfunctional or suppressed immune system (by using immunosuppressants, etc.), in the same household.
  • Persons with a prior history of hypersensitivity to chicken eggs or chicken egg proteins or components of the trial vaccine (such as sucrose, phosphoric acid, glutamate, arginine and acid-hydrolyzed pig gelatin).
  • Persons inoculated with a live virus vaccine within 1 month before screening.
  • Persons having the planned administration of another trial vaccine or drug during the period from one month before screening to the completion of the trial
  • Person having an influenza treatment drug (such as commercially available drugs or trial vaccines: for example, Oseltamivir, Zanamivir, Amantadine, etc.), administered within one month before screening. Incidentally, no prophylactic administration of an influenza viral drug was permitted.
  • Persons inoculated with an influenza vaccine within 6 months before screening or planned to be inoculated with an influenza vaccine during the term of the present trial.
  • Persons with blood drawn quantity (including blood donation) of 400 mL or more within 3 months or 200 mL or more within 1 month before screening.
  • Persons with a history of any febrile disorders (oral cavity temperature ³ 38.0°C) or other acute disorders within 36 hours before trial vaccine inoculation.
  • Persons who had upper respiratory tract disorders themselves or whose family members had such disorders within 72 hours before trial vaccine inoculation.
  • Persons treated with an antibiotic within 72 hours before trial vaccine inoculation.
  • Persons with an acute asthmatic symptom.
  • Persons judged to have a pathology preventing the evaluation of the trial effect by the principal investigator (or investigator).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00224783

Sponsors and Collaborators
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Robert Walker, MD MedImmune LLC
  More Information

No publications provided

Responsible Party: Christopher Ambrose, MD, Medimmune, LLC
ClinicalTrials.gov Identifier: NCT00224783     History of Changes
Obsolete Identifiers: NCT00192530
Other Study ID Numbers: D153 P800
Study First Received: September 20, 2005
Last Updated: January 25, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Potassium phosphate
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 31, 2014